A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)

Study Status

Open to Enrollment

Study Description

Vosaroxin is an experimental medication and has been given to more than 550 people with different kinds of cancer, including Acute Myeloid Leukemia (AML). Cytarabine is a marketed medication commonly used in the treatment of AML.

This study is being done to find out how effective and safe vosaroxin in combination with cytarabine is compared to with using cytarabien without vosaroxin. Patients will be randomized to one of two study groups:

  • Group A: Vosaroxin and cytarabine
  • Group B: Placebo and cytarabine

The study will determine if survival is different between the two treatment groups.

Disease Status and/or Stage

Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia


Sunesis Pharmaceuticals

Key Eligibility

  • Men and women age 18 and older
  • Diagnosis of Acute Myeloid Leukemia (AML)
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Ellen Ritchie, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page